Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (June, 10.1007/s40121-021-00455-1, 2021)

被引：0

作者：

Aghemo, Alessio ^{[1
,24
]}

Horsmans, Yves ^{[2
]}

Bourgeois, Stefan ^{[3
]}

Bondin, Mark ^{[4
]}

Gschwantler, Michael ^{[5
,6
]}

Hofer, Harald ^{[7
]}

Semmo, Nasser ^{[8
]}

Negro, Francesco ^{[9
,27
]}

Zhang, Zhenzhen ^{[4
]}

Marcinak, John ^{[4
]}

Veitsman, Ella ^{[10
]}

Hazzan, Rawi ^{[11
]}

Mimidis, Konstantinos ^{[12
]}

Goulis, Ioannis ^{[13
]}

Marques, Nuno ^{[14
]}

Flisiak, Robert ^{[15
]}

Mazur, Wlodzimierz ^{[16
]}

Roncero, Carlos ^{[17
,25
,26
]}

Marra, Fiona ^{[18
]}

Pageaux, Georges Philippe ^{[19
]}

Asselah, Tarik ^{[20
,21
]}

Lampertico, Pietro ^{[22
,23
]}

机构：

[1] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

[2] UCL, Clin Univ St Luc, Brussels, Belgium

[3] Stuivenberg ZNA, Antwerp, Belgium

[4] AbbVie Inc, N Chicago, IL USA

[5] Sigmund Freud Univ, Dept Internal Med 4, Wilhelminenspital, Vienna, Austria

[6] Sigmund Freud Univ, Vienna, Austria

[7] Klinikum Wels Grieskirchen, Dept Internal Med Gastroenterol & Hepatol, Wels, Austria

[8] Univ Bern, Dept BioMed Res Hepatol, Inselspital, CH-3010 Bern, Switzerland

[9] Univ Hosp, Div Gastroenterol & Hepatol, Geneva, Switzerland

[10] Liver Unit, Rambam Hlth Care Campus, Haifa, Israel

[11] Emek Med Ctr, Afula, Israel

[12] Democritus Univ Thrace, Sch Med, Dept Internal Med 1, Alexandroupolis, Greece

[13] Aristotle Univ Thessaloniki, Dept Internal Med 4, Thessaloniki, Greece

[14] Hosp Garcia Orta EPE, Infect Dis Serv, Almada, Portugal

[15] Med Univ Bialystok, Dept Infect Dis & Hepatol, Bialystok, Poland

[16] Med Univ Silesia, Clin Dept Infect Dis, Katowice, Poland

[17] Univ Salamanca Hlth Care Complex, Psychiat Serv, Salamanca, Spain

[18] Univ Liverpool, Hepatol Drug Interact Grp, Liverpool, Merseyside, England

[19] Ctr Hosp Univ CHU Montpellier, Dept Hepato Gastro Enterol, Montpellier 5, France

[20] Univ Paris, Hop Beaujon, AP HP, Dept Hepatol, Clichy, France

[21] Univ Paris, INSERM UMR 1149, Clichy, France

[22] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Policlin Div Gastroenterol & Hepatol CRC AM & A M, Ctr Liver Dis, Milan, Italy

[23] Univ Milan, Milan, Italy

[24] Humanitas Res Hosp IRCCS, Div Internal Med & Hepatol, Dept Gastroenterol, Via Manzoni 56, I-20089 Milan, Italy

[25] Univ Salamanca, Inst Biomed, Salamanca, Spain

[26] Univ Salamanca, Sch Med, Salamanca, Spain

[27] Univ Hosp, Div Clin Pathol, Geneva, Switzerland

来源：

INFECTIOUS DISEASES AND THERAPY | 2021年 / 10卷 / 04期

关键词：

Alcohol use disorder; Health-related quality of life; Hepatitis C; Illicit drugs; Psychiatric disorders;

D O I：

10.1007/s40121-021-00529-0

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1–6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient populations, focusing on persons who use drugs infected with HCV. Methods: Data were pooled from nine countries (13 November 2017–31 January 2020). Patients had HCV GT1–6, with or without compensated cirrhosis, with or without prior HCV treatment and received glecaprevir/pibrentasvir consistent with local label at their physician’s discretion. Patients with prior direct-acting antiviral exposure were excluded from efficacy and quality-of-life analyses. The percentage of patients achieving sustained virologic response at post-treatment week 12 (SVR12) was assessed. Mean changes from baseline to SVR12 visit in 36-Item Short-Form Health Survey mental and physical component summary scores were reported. Safety was assessed in patients receiving at least one dose of glecaprevir/pibrentasvir. Results: Of 2036 patients, 1701 (83.5%) received 8-week glecaprevir/pibrentasvir. In 1684 patients with sufficient follow-up, SVR12 rates were 98.0% (1651/1684) overall, 98.1% (1432/1459) in 8-week treated patients, 97.0% (519/535) in persons who use drugs, and greater than 95% across subgroups. Mean changes from baseline in mental and physical component summary scores were 3.7 and 2.4, respectively. One glecaprevir/pibrentasvir-related serious adverse event was reported; six glecaprevir/pibrentasvir-related adverse events led to discontinuation. Conclusions: Glecaprevir/pibrentasvir was highly effective, well tolerated, and improved quality of life in HCV-infected persons who use drugs and other underserved patients. Trial Registration: These multinational post-marketing observational studies are registered with ClinicalTrials.gov, number NCT03303599. © 2021, The Author(s).

引用

页码：2223 / 2225

页数：3